Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Pemetrexed Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG105

    Antineoplastic Agent - Pemetrexed Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG105 alerts

    Get alerted when Policy CG105 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization exceptions for non-preferred, physician-administered pemetrexed products under the medical benefit. It applies to members requesting a non-preferred product and establishes preferred products, exception criteria, documentation requirements, authorization duration, exclusions, and applicable billing codes.

    Policy Summary
    PayerOscar Health
    PolicyAntineoplastic Agent - Pemetrexed Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG105
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for non-preferred products and include one qualifying exception criterion with supporting clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred pemetrexed products
    5Non-preferred pemetrexed products
    2Required exception criteria
    12 monthsMaximum authorization period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 monthsInitial shortage authorization

    Non-preferred Product Coverage Criteria

    Non-preferred Product Exception

    Coverage for a non-preferred product will be provided when BOTH of the following criteria are met:

    Non-preferred product exception

    • ONE qualifying exception criterion

      • Drug shortage or unavailability of all preferred products.
      • Hypersensitivity to specific excipients precluding use of all preferred products.
      • For ready-to-use formulations only, such as Pemrydi RTU, documented clinical necessity due to documented safety concerns with reconstitution or preparation.
      • The therapy regimen is one for which clinical evidence and/or current treatment guidelines, such as NCCN, support preferential use of the requested product over all preferred products.
      • The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.

        Subject to applicable state requirements.

    • Supporting clinical documentation: Clinical documentation is provided to support the exception request, including, as applicable, notification of drug shortage or unavailability; facility safety protocols necessitating use of a ready-to-use formulation; previous treatment history, including adverse reactions or treatment failures with preferred products; and the specific reason preferred products cannot be used.

      Examples are not exhaustive.

    Non-preferred pemetrexed products are not covered when used for experimental, investigational, or unproven indications. This includes uses outside FDA-approved labeling or not supported by current medical evidence and standards of care, unsupported non-FDA-approved or off-label uses, doses exceeding FDA-approved labeling or clinical practice guidelines without sufficient evidence, and other uses not clinically appropriate.

    Use of a non-preferred product is considered not medically necessary when it is not required to treat or manage the member’s medical condition, is not aligned with generally accepted medical practice, or is used primarily for the convenience of the member, family, or provider.

    Pemetrexed Product Coding

    Preferred products / medically necessary when criteria are metHCPCSCovered
    J9294Hospira 505(b)(2) Injection, pemetrexed (hospira) not therapeutically equivalent to J9305, 10 mg
    J9305Alimta Injection, pemetrexed, not otherwise specified, 10 mg
    Non-preferred products / exception reviewHCPCSCovered
    J9292Axtle Injection, pemetrexed dipotassium, 10 mg
    J9304Pemfexy Injection, pemetrexed (pemfexy), 10 mg
    J9314Teva 505(b)(2) Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg
    J9322Bluepoint 505(b)(2) Injection, pemetrexed (bluepoint) not therapeutically equivalent to J9305, 10 mg
    J9324Pemrydi RTU Injection, pemetrexed (pemrydi rtu), 10 mg

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Submit Prior Authorization Requests

    Submit oncology prior authorization requests to EviCore through the applicable submission channel before treatment with the requested product.

    • Submit through the EviCore provider portal at www.evicore.com or call 855-252-1118.
    Prior Authorization

    Meet Both Exception Requirements

    A non-preferred product is covered only when the member meets both requirements: at least one qualifying exception criterion and supporting clinical documentation.

    • Qualifying exceptions may include shortage or unavailability of all preferred products, hypersensitivity to excipients, documented safety concerns with reconstitution or preparation of ready-to-use formulations, evidence or guideline support favoring the requested product, or a state prohibition on prerequisite trials.
    • Provide documentation supporting the applicable exception.

    Unsupported block type: step_therapyリ

    Policy Background

    Pemetrexed products are physician-administered antineoplastic therapies covered under the medical benefit. This policy addresses prior authorization exceptions for non-preferred pemetrexed products and establishes the requirements for an exception to the Plan’s preferred product list; it does not establish disease-specific indications in the clinical indications section.

    Policy Definitions

    Compendia
    MeaningSummaries of drug information and medical evidence used to support decisions about the appropriate use of drugs and medical procedures.
    ExamplesExamples include American Hospital Formulary Service Drug Information, Elsevier Clinical Pharmacology, and the National Comprehensive Cancer Network Drugs and Biologics Compendium.
    Additional sourcesOther examples include Thomson Micromedex DrugDex and the United States Pharmacopeia-National Formulary (USP-NF).
    Contraindication
    MeaningA pre-existing condition or factor that precludes use of a drug.
    BasisThe condition or factor prevents use because of risk of harm.

    Initial Exception Approval

    Initial Exception Approval

    A non-preferred product is covered when BOTH of the following are present:

    Initial non-preferred product exception

    • ONE qualifying exception criterion

      • Drug shortage or unavailability of all preferred products.
      • Hypersensitivity to specific excipients precluding use of all preferred products.
      • For ready-to-use formulations only, such as Pemrydi RTU, documented clinical necessity due to documented safety concerns with reconstitution or preparation.
      • The therapy regimen is one for which clinical evidence and/or current treatment guidelines, such as NCCN, support preferential use of the requested product over all preferred products.

    Shortage-Based Continuation

    Shortage-Based Continuation

    For a non-preferred product requested because of drug shortage or unavailability:

    Shortage-based continuation: The initial authorization may be extended when continued documentation supports that the drug shortage or unavailability continues.Initial approval: up to 3 months

    If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

    Preferred Product Step Therapy

    StepRequirementException pathway
    1Try all applicable preferred medications first when they are considered safe and effective by the provider.An exception may be considered when the member has documented trial and failure, inadequate response, intolerance, or contraindication to all applicable preferred products.

    Authorization Duration

    Authorization Period
    ProductNon-preferred pemetrexed product.
    Maximum authorizationUp to 12 months.
    ConditionApplies when the prior authorization criteria are met.
    Shortage or Unavailability Authorization
    ProductNon-preferred pemetrexed product requested because of drug shortage or unavailability.
    Initial authorizationUp to 3 months.
    ExtensionMay be extended based on continued documentation of the shortage or unavailability.
    Policy Summary
    PayerOscar Health
    PolicyAntineoplastic Agent - Pemetrexed Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG105
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for non-preferred products and include one qualifying exception criterion with supporting clinical documentation.
    SourceLink
    On This Page
    Non-preferred Product Coverage CriteriaPemetrexed Product CodingPrior Authorization and Documentation RequirementsPolicy BackgroundPolicy DefinitionsInitial Exception ApprovalShortage-Based ContinuationPreferred Product Step TherapyAuthorization Duration
    Documentation Required

    Support the Exception With Documentation

    Provide clinical documentation that supports the specific exception being requested. Documentation may include shortage or unavailability notices, facility safety protocols, treatment history, adverse reactions or treatment failures, and the specific reason preferred products cannot be used.

    • The request must include documentation supporting the qualifying exception.
    Documentation Required

    Provide Acceptable Clinical Records

    Submit records that establish the diagnosis, relevant clinical circumstances, and prior use or inability to use preferred alternatives.

    • Up-to-date chart notes.
    • Relevant test results and/or imaging reports.
    • Prescription claims records and/or prescription receipts supporting prior trials of alternatives.
    Denial Risk

    Exception Criteria Not Met

    A non-preferred product may be denied when the member does not meet at least one qualifying exception criterion or when supporting clinical documentation is not provided.

    • Both the exception criterion and the documentation requirement must be satisfied.
    Denial Risk

    Experimental, Investigational, or Unproven Use

    Do not request coverage for a non-preferred product when it is used for an experimental, investigational, or unproven indication. Such use includes indications outside FDA-approved labeling or not supported by current medical evidence and standards of care.

    • Coverage is not provided for unsupported off-label use, excessive dosing without sufficient evidence, use not required to treat or manage the condition, use inconsistent with generally accepted medical practice, or use primarily for convenience.
    Prior Authorization

    Shortage Resolved

    For a shortage or unavailability exception, the initial authorization may be limited to up to 3 months and may be extended only with continued documentation that the shortage or unavailability persists.

    • If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to a preferred product at the next authorization period.
    Coverage relevanceA documented contraindication may support an exception when preferred products cannot be used.
    Intolerance
    MeaningThe inability to tolerate or endure a medication or treatment.
    Typical causesIntolerance may result from difficult or harmful side effects, reactions, or hypersensitivities.
    Required detailDocumentation should describe the specific intolerable effects and their impact on quality of life, adherence, or overall health.
    Documentation
    MeaningWritten information supporting the requested treatment or exception.
    Clinical recordsMay include up-to-date chart notes, relevant test results, and relevant imaging reports supporting diagnoses.
    Treatment historyMay include prescription claims records and prescription receipts supporting prior trials of alternatives.
    Experimental or Investigational
    MeaningA procedure, drug, or device that has not been proven effective or has not been approved by the appropriate regulatory bodies.
    Effectiveness statusThe treatment has not been proven effective.
    Regulatory statusThe treatment has not been approved by the appropriate regulatory bodies.
    Medical Benefit Preferred Drug Exceptions Criteria
    MeaningPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Preferred-drug requirementRequirements may include a trial and failure of preferred drugs first.
    PurposeThe criteria determine whether a non-preferred drug qualifies for coverage under the medical benefit.
  1. The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.

    Subject to applicable state requirements.

  2. Supporting clinical documentation: Clinical documentation is provided to support the exception request, including, as applicable, notification of drug shortage or unavailability; facility safety protocols necessitating use of a ready-to-use formulation; previous treatment history, including adverse reactions or treatment failures with preferred products; and the specific reason preferred products cannot be used.

    Examples are not exhaustive.